ArticleCost effectiveness and resource allocation : C/E2026

A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis.

Jiatai Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.